Sickle cell disease (SCD) is a lifelong inherited blood disorder with no one-size-fits-all approach to management. The misshapen red blood cells it produces can block blood vessels, starve organs of oxygen, and trigger intense pain episodes at any time. Yet with the right combination of lifestyle adjustments and medical interventions, the frequency and severity of these complications can be significantly reduced. Here is a clear look at what managing SCD actually involves – from daily habits to potentially curative treatments.
Table of Contents
Lifestyle management for prevention
According to the CDC, there are concrete steps people with SCD can take every day to reduce the likelihood of a painful crisis. These include drinking plenty of water to stay hydrated, avoiding extremes of temperature (both heat and cold), and steering clear of environments with low oxygen levels – such as high-altitude locations, unpressurised aircraft cabins, or situations involving strenuous exercise without adequate preparation. Mayo Clinic also recommends eating a balanced diet rich in folic acid, which the bone marrow requires to produce new red blood cells. Supplementing with folic acid daily is commonly advised by healthcare providers.
Good hygiene practices – regular handwashing, dental care, and avoiding contact with sick individuals – help lower the risk of infections, to which people with SCD are especially susceptible. Beyond the physical, mental health support is a vital and often overlooked part of SCD management. Living with a chronic, unpredictable condition takes a significant psychological toll. Access to counselling, peer support groups, and adaptive coping strategies are all essential parts of a comprehensive care plan.
Preventing and treating infections
People with SCD – particularly children – face a significantly higher risk of life-threatening bacterial infections. This is because the spleen, which normally filters bacteria from the blood, is damaged early in life by repeated sickling episodes. The National Heart, Lung, and Blood Institute (NHLBI) recommends that children with the most severe form of the disease (HbSS) receive daily oral penicillin from birth until at least age five to dramatically reduce the risk of potentially fatal infections such as pneumococcal sepsis.
Vaccination is equally important. Recommended vaccines for people with SCD include those for pneumococcus, influenza, meningococcus, and Haemophilus influenzae type b. These are not optional extras – they are core components of preventive care. The CDC explicitly includes vaccinations and antibiotic prophylaxis among the primary strategies for managing SCD complications from childhood onwards.
Pain management with hydroxyurea
Pain crises – medically known as vaso-occlusive crises – are the most common reason people with SCD are hospitalised. Mild to moderate pain may be managed with over-the-counter analgesics such as acetaminophen or ibuprofen, while severe crises often require prescription opioids administered in a clinical setting. But the goal is not just to treat pain after it occurs – it is to prevent it from happening as often.
This is where hydroxyurea plays a central role. A 2024 review published in PMC confirms that hydroxyurea has remained the cornerstone of SCD therapy since its pivotal clinical trial in 1995, which demonstrated a significant reduction in vaso-occlusive crises and blood transfusions. It works primarily by increasing levels of fetal haemoglobin (HbF) in the blood – a form of haemoglobin that does not sickle – and also reduces white blood cell and platelet counts, decreasing the tendency of sickled cells to stick to blood vessel walls.
The NHLBI reports that in adults, hydroxyurea reduces the frequency of pain crises and acute chest syndrome, improves anaemia, and lowers the need for blood transfusions and hospital admissions. In children, studies show it can prevent pain episodes and reduce hospitalisations, with one study in infants between 9 and 18 months demonstrating fewer pain events and episodes of dactylitis (painful swelling of the fingers and toes). However, hydroxyurea is not suitable for everyone – it cannot be taken during pregnancy, and patients require regular blood monitoring to check for side effects such as low white blood cell counts.
The role of blood transfusions
Blood transfusions serve several purposes in SCD management. They increase the number of healthy (non-sickled) red blood cells in circulation, which helps improve oxygen delivery and reduces the proportion of haemoglobin S (HbS) in the blood. According to Mayo Clinic, transfusions are used to treat and prevent serious complications including stroke, severe anaemia, and acute chest syndrome.
Transfusions may be given in different ways depending on the situation:
- Acute transfusions are used during emergencies such as a severe drop in haemoglobin, acute chest syndrome, or multi-organ failure.
- Intermittent transfusions are given for specific complications when they arise.
- Regular (chronic) transfusions are used for long-term stroke prevention, particularly in children identified as high risk through transcranial Doppler ultrasound. Medscape’s clinical guidelines note that the landmark STOP trial showed regular transfusions produced a 90% reduction in first stroke in high-risk children.
Despite their benefits, transfusions come with risks. These include alloimmunisation (where the immune system attacks donor blood cells, making future matching harder), infection risk, and iron overload – a particularly serious long-term consequence of repeated transfusions.
Iron chelation therapy
Each unit of donated blood introduces iron into the body. The human body has no efficient mechanism to excrete excess iron, so patients who receive multiple transfusions over time inevitably accumulate iron in their organs. As documented in PubMed, if left untreated, this iron overload leads to organ failure and death, with the heart, liver, and endocrine glands being particularly vulnerable.
Iron chelation therapy is the treatment used to remove this excess iron. Chelating agents bind to iron in the bloodstream or tissues and allow it to be excreted from the body through urine and faeces. A clinical review published in PMC identifies three chelating agents currently in use: deferoxamine (DFO), which is given by subcutaneous or intravenous injection; and two oral agents, deferiprone and deferasirox. Oral chelators have become increasingly important because the demanding schedule of DFO injections – often administered over 8-12 hours, up to seven days a week – makes adherence very difficult, particularly for younger patients.
Research shows that iron chelation therapy results in better overall survival in SCD, especially when started early. Iron levels are monitored regularly through blood ferritin tests and MRI imaging of the liver and heart to guide dosing decisions. Patient adherence to the prescribed regimen is, according to clinicians, the single most important factor determining whether chelation therapy succeeds.
Bone marrow transplant: a potential cure
For most of SCD’s history, treatment has focused on managing symptoms rather than eliminating the disease. A bone marrow transplant – more precisely called a haematopoietic stem cell transplant (HSCT) – is the only currently available treatment that can potentially cure the condition outright. The procedure replaces the patient’s disease-producing bone marrow with healthy stem cells from a compatible donor, after which the new marrow begins producing red blood cells that do not contain abnormal haemoglobin S.
The NHLBI explains that transplants require a well-matched donor – ideally a close blood relative – and success depends on human leukocyte antigen (HLA) compatibility testing. According to StatPearls (NCBI), HSCT has been performed for SCD since 1984 and results are best in children, particularly those under 10 years of age. When a matched sibling donor is available, disease-free survival rates exceed 85%.
However, access to this treatment is significantly limited by two factors. First, only a small proportion of patients have a fully matched sibling donor – the most suitable source. Second, the procedure itself carries substantial risks. These include graft-versus-host disease (GVHD), where the transplanted immune cells attack the recipient’s own body; infection during the period of immune suppression; and graft failure. The NHLBI notes that approximately 5% of recipients under 16 and around 9% of those aged 16 and older have died following the transplant procedure. For patients without a matched family donor, newer approaches – including haploidentical (half-matched) transplants and gene therapies such as Casgevy and Lyfgenia – are being actively developed and studied, offering expanding hope for a wider population.
A holistic approach to SCD management
Managing sickle cell disease is never a single intervention – it is a lifelong, layered effort. Everyday lifestyle choices reduce crisis triggers. Vaccinations and antibiotics guard against infections. Hydroxyurea modifies the course of the disease. Blood transfusions address acute and chronic complications. Iron chelation counters the side effects of those transfusions. And for a carefully selected group of patients, a bone marrow transplant offers the chance of a permanent cure. Working closely with a specialist medical team – typically led by a haematologist – to build an individualised treatment plan remains the most effective way to manage this complex, demanding condition and improve quality of life.
What do you think? Given that bone marrow transplants currently offer the only potential cure for sickle cell disease but remain inaccessible to most patients due to donor limitations and procedural risks, how should healthcare systems prioritise investment – in expanding transplant access, or in developing better long-term disease management options? And considering that patient adherence is the biggest barrier to the success of iron chelation therapy, what role should schools and communities play in supporting young people with SCD to stay consistent with their treatment?
References
- https://www.cdc.gov/sickle-cell/about/prevention-and-treatment.html
- https://www.mayoclinic.org/diseases-conditions/sickle-cell-anemia/diagnosis-treatment/drc-20355882
- https://www.nhlbi.nih.gov/health/sickle-cell-disease/treatment
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11546997/
- https://emedicine.medscape.com/article/205926-treatment
- https://pubmed.ncbi.nlm.nih.gov/15511620/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5444974/
- https://sickle-cell.com/iron-chelation
- https://www.ncbi.nlm.nih.gov/books/NBK538515/
Leave a Reply